Slide thumbnail

17-20 SEPTEMBER 2019

Cambridge, UK

RNA epigenetics in human disease

Speakers

The organisers are delighted to confirm the following speakers will be presenting at the conference.

Reuven Agami

Reuven Agami

Shankar Balasubramanian

Shankar Balasubramanian


Professor Shankar Balasubramanian

Herchel Smith Professor of Medicinal Chemistry

University of Cambridge

Sir Shankar Balasubramanian is the Herchel Smith Professor of Medicinal Chemistry at the University of Cambridge and senior group leader at the Cambridge Institute. He works on the chemistry, structure and function of nucleic acids. He is a co-inventor of the leading next generation DNA sequencing methodology, Solexa sequencing (now Illumina) that has made routine, accurate, low-cost sequencing of human genomes a reality and has revolutionised biology. He has worked on the identification, elucidation and manipulation of non-coding genetic elements, particularly four-stranded structures called G-quadruplexes. His work on the intervention of nucleic acid function using small molecules has revealed a number of molecular mechanisms that can be exploited, e.g. to modulate the biology of cancer. His more recent contributions include the development of methods for sequencing the epigenetic DNA bases 5-methylcytosine, 5-hydroxymethylcytosine and 5-formylcytosine at single base resolution, as part of a broader investigation of the importance of wider, natural DNA alphabet. His collective contributions span fundamental chemistry and its application to the biological and medical sciences. Sir Shankar was knighted in the Queen’s New Year’s Honours in 2017 for his services to science and medicine and awarded the Royal Society’s Royal Medal in 2018.

Thomas Carell

Thomas Carell


Professor Thomas Carell

Professor for Chemistry

LMU Munich

Thomas Carell (Ph. D) was raised in Bad-Salzuflen (Germany). He studied chemistry at the Universities of Münster and Heidelberg. In 1993 he obtained his doctorate with Prof. H. A. Staab at the Max Planck Institute of Medical Research in Heidelberg. After postdoctoral training with Prof. J. Rebek at MIT (Cambridge, USA) in 1993-1995, Thomas Carell moved to the ETH Zürich (Switzerland) as an assistant professor to start independent research. He obtained his habilitation (tenure) in 2000. He subsequently accepted a full professor position for Organic Chemistry at the Philipps-Universität in Marburg (Germany). In 2004 Thomas Carell moved to the Ludwig-Maximilians-Universität (LMU) in Munich (Germany), where he is heading a research group centered around chemical biology. The current focus is to analyze the chemistry of epigenetic programming in DNA and RNA. Thomas Carell founded the company Baseclick GmBH in 2008. He is a member of the National German Academy, Leopoldina and of the Berlin-Brandenburg Academy of Arts and Sciences. He is a recipient of the Cross of Merit from the Federal Republic of Germany. Thomas Carell obtained the Leibniz award from the DFG in 2003 (comparable to an HHMI investigator in the USA) and an ERC advanced grant in 2017. Thomas Carell is the speaker of the Excellence Cluster (EXC114) on protein chemistry and of the collaborative research center (SFB749) on Chemical Dynamics.

Robert Copeland

Robert Copeland


Dr Robert A. Copeland

President, Chief Scientific Officer & Co-founder

Accent Therapeutics, Inc.

Robert A. Copeland, Ph.D. is President, Chief Scientific Officer and Co-Founder of Accent Therapeutics and also President of the independent consulting firm, Ki Consultant, LLC. He was formerly President of Research and Chief Scientific Officer of Epizyme, Inc. and before that, Vice President of Cancer Biology, Oncology Center of Excellence in Drug Discovery, GlaxoSmithKline. Dr. Copeland received his doctorate in chemistry from Princeton University and did postdoctoral studies as the Chaim Weizmann Fellow at the California Institute of Technology. He has contributed to drug discovery and development efforts leading to 18 investigational new drugs entering human clinical trials. These include the cancer drugs foretinib, afuresertib, pinometostat, tazemetostat, Tafinlar (dabrafenib) and Mekinist (trametinib) and the antibiotic Altabax (retapamulin). Dr. Copeland has contributed more than 200 publications to the scientific literature, holds 14 issued U.S. patents and has authored 5 books in the areas of protein science and enzymology. His most recent book, Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists, 2nd Edition (Wiley, Hoboken, NJ), published in March 2013. In 2016 Dr. Copeland was elected a Fellow of the American Association for the Advancement of Science (AAAS).

Valérie de Crécy-Lagard

Valérie de Crécy-Lagard


Valérie de Crécy-Lagard

After a PhD in microbial genetics at the Pasteur Institute (Paris), Valérie de Crécy-Lagard worked in academic and industrial settings using the power of bacterial genetics to study primary and secondary metabolism as well as mechanisms of regulation by proteolysis. In the past 20 years, her work has focused on combining comparative genomic analysis with experimental methods to discover the function of the many ‘unknowns’ found in sequenced genomes, first at the Scripps Research Institute and then, since 2004, in the Microbiology and Cell Science Department at the University of Florida. This led to solving many long-standing mysteries, particularly in the fields of coenzyme metabolism and transfer RNA (tRNA) modification. In parallel, she collaborates with biotech groups on using long-term cultures to evolve microorganisms with specific traits. Full Bibliography: 136 peer reviewed publications, h-index 45 Google Scholar Profile

Michaela Frye

Michaela Frye


Prof Michaela Frye

PI

German Cancer Research Center - DKFZ

Michaela Frye completed her PhD in Frankfurt/Main in Germany in 2000 studying the role of epithelial defensins in Cystic Fibrosis. In 2001, she joined Cancer Research UK (CR-UK) in London as a Postdoctoral Fellow, where she developed her fascination for the question how stem cells form and maintain adult tissues. In 2007, Michaela started her independent research group at the Wellcome Trust – Medical Research Council Cambridge Stem Cell Institute. She received a CR-UK Career Development Fellowship in 2007 and a CR-UK Senior Fellowship and an ERC Consolidator Grant in 2013 to study how dysregulation of stem cell function contributes to human diseases and cancer. In 2019 she has accepted a Professorship at the DKFZ in Heidelberg Germany.

Francois Fuks

Francois Fuks

Richard Gregory

Richard Gregory


Richard Gregory

Principal Investigator

Boston Children's Hospital

Richard I. Gregory. Ph.D. is Professor in the Departments of Biological Chemistry and Molecular Pharmacology, and Pediatrics at Harvard Medical School, and Principal Investigator in The Stem Cell Program in the Division of Hematology/Oncology at Boston Children’s Hospital. He is also co-Director and executive committee member of the Harvard Initiative for RNA Medicine, and Principal faculty member of The Harvard Stem Cell Institute. His undergraduate studies were at the University of Liverpool, UK, and he received a Ph.D. from Cambridge University in 2001, for research performed at the Babraham Institute, Cambridge. He did his postdoctoral work at the Fox Chase Cancer Center and the Wistar Institute, Philadelphia. His postdoctoral research focused on mechanisms of microRNA biogenesis, and was supported by a Jane Coffin Childs Research Fellowship. Since its establishment in 2006 research in the Gregory laboratory has focused on understanding molecular and cellular mechanisms of RNA regulation and the relevance of these pathways in stem cell biology, development, and human diseases including cancer.

Chuan He

Chuan He


Chuan He

Professor

The University of Chicago

Stacy Horner

Stacy Horner


Dr Stacy Horner

Assistant Professor

Duke University Medical Center

Dr. Stacy M. Horner is currently an Assistant Professor in the departments of Molecular Genetics & Microbiology and Medicine at the Duke University School of Medicine, where she is also the Co-director for the Duke Center for RNA Biology. Stacy received her Ph.D. in 2007 from Yale University, where she studied human papillomaviruses under the mentorship of Dr. Daniel DiMaio. Her postdoctoral research, sponsored by Irvington Institute Fellowship Program of the Cancer Research Institute, was with Dr. Michael Gale at the University of Washington, and focused on hepatitis C virus regulation of antiviral innate immunity. She started her independent lab at Duke in 2013. Research in her laboratory is defining the virus-host interactions that control the outcome of infection to hepatitis C virus and other viruses in the Flaviviridae family. She and her team are also identifying the molecular mechanisms of how these viruses activate and evade host innate immune defenses, as well as deciphering how the RNA modification N6-methyladeonsine regulates Flaviviridae virus infection and antiviral innate immunity. Stacy has received the Ann Palmenberg Junior Investigator Award from the American Society for Virology, the ASM Microbe Junior Investigator Award, and both the Milstein Young Investigator Award and the Christina Fleischmann Award from the Cytokines Society. She is also currently a Burroughs Wellcome Fund Investigator in the Pathogenesis of Infectious Disease.

Samie Jaffrey

Samie Jaffrey


Professor Samie Jaffrey

Professor

Weill Medical College, Cornell University

Dr. Samie Jaffrey is the Greenberg-Starr Professor in the Department of Pharmacology at the Weill Cornell Medical College. He received an M.D. and Ph.D. in 1999 from Johns Hopkins School of Medicine where he studied mechanisms of nitric oxide signaling with Dr. Solomon H. Snyder and started his own laboratory at Weill Cornell Medical College in 2001. Dr. Jaffrey’s work has fundamentally advanced our understanding of RNA biology and gene regulation. His lab developed genetically encoded fluorescent RNAs for imaging RNA localization and trafficking in live cells, including the Spinach-tagged RNAs. He has extended this technology to create a new class of genetically encoded biosensors composed of RNA that allows signaling molecules to be imaged in living cells. Most recently, he has helped to launch the field of “epitranscriptomics,” which relates to the diverse nucleotide modifications that impact the fate and function of mRNA and long noncoding RNAs in cells. Dr. Jaffrey’s transcriptome-wide mapping of N6-methyladenosine (m6A) in 2012 revealed that m6A is a pervasive modification in the transcriptome, thereby identifying this modification as a fundamentally novel form post-transcriptional mRNA regulation. Since this seminal study, Dr. Jaffrey mapped dimethyladenosine (m6Am) and established functions of m6A and m6Am as well as m6A and m6Am reader, writer, and eraser proteins.

Narry Kim

Narry Kim

Tony Kouzarides

Tony Kouzarides


Tony Kouzarides

Jeannie Lee

Jeannie Lee

Michal Minczuk

Michal Minczuk

Eric Miska

Eric Miska


Eric Miska

Gerhard Müller

Gerhard Müller

Chief Scientific Officer

Gotham Therapeutics

Oliver Rausch

Oliver Rausch


Dr Oliver Rausch

Chief Scientific Officer

Storm Therapeutics

Oliver Rausch is Chief Scientific Officer at Storm Therapeutics Ltd. Storm is a spin-out from Cambridge University targeting RNA modification pathways for the development of a new class of anti-cancer treatments. As CSO, Oliver has overall responsibility for developing Storm’s target discovery platform, and for delivering small molecule drugs from its emerging drug discovery pipeline. Oliver worked closely with Storm’s scientific founders, Profs Tony Kouzarides and Eric Miska, to establish Storm, and joined Storm full time in October 2016. Prior to Storm, Oliver was Programme Director at the UK’s National Institute for Health Research (NIHR) where he developed and led a number of high profile industry collaboration programmes in clinical translational research and experimental medicine. Oliver has over twenty years of drug discovery and development experience in Inflammation, Neurology and Oncology, including from organisations such as GlaxoSmithKline, UCB Celltech and Cellzome. He holds a degree in Biochemistry from the Free University in Berlin and a PhD in Biochemistry and Cell Biology from the Institute of Cancer Research in London.

Gidi Rechavi

Gidi Rechavi


Professor Gidi Rechavi

Head, Sheba Cancer Research Center

Sheba Medical Center

Schraga Schwartz

Schraga Schwartz


Schraga Schwartz

Tom Suzuki

Tom Suzuki


Dr Tom Suzuki

Professor

University of Tokyo

© Copyright - STORM Therapeutics 2019